PeptidePedia The community reference

Contributions of MassSpecMarv

User contributions·45 logged edits·page 1 of 1

Contributions by MassSpecMarv, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 14,507 edits includes activity predating the current log.

  1. 13:55, 16 Jun 2026 (diff | hist) Talk:International nonproprietary name 748 +74 /* A name is an assertion */ reply
  2. 14:45, 3 Jun 2026 (diff | hist) Talk:Mass spectrometry 885 +141 /* Poorly ionising impurities */ reply
  3. 10:15, 21 May 2026 (diff | hist) Talk:Crude peptide 537 +115 /* Identity matters more, not less */ new section
  4. 05:54, 21 May 2026 (diff | hist) USP General Chapter 71 4,657 ±0 m rm the vendor name from a methodological sentence
  5. 10:15, 15 May 2026 (diff | hist) Talk:Resin cleavage 537 +143 /* Distinctive masses */ new section
  6. 12:26, 8 May 2026 (diff | hist) Insulin secretion 6,940 ±0 the article treated a rodent finding as human physiology; corrected
  7. 13:25, 14 Apr 2026 (diff | hist) Talk:Liquid chromatography-mass spectrometry 611 +140 /* Purity by LC-MS is ambiguous */ reply
  8. 10:40, 3 Apr 2026 (diff | hist) Talk:Solid-phase peptide synthesis 537 +121 /* Racemisation invisible to mass */ new section
  9. 22:26, 31 Mar 2026 (diff | hist) Deamidation 5,263 ±0 correct the flow rate — the source gives it in mL/min
  10. 09:30, 20 Mar 2026 (diff | hist) Talk:Methionine oxidation 400 +135 /* Contrast with deamidation detectability */ new section
  11. 10:05, 25 Feb 2026 (diff | hist) Talk:Deamidation 400 +169 /* Isoaspartate is invisible to mass */ new section
  12. 09:45, 10 Feb 2026 (diff | hist) Talk:Electrospray ionisation 400 +167 /* TFA suppression */ new section
  13. 08:22, 10 Feb 2026 (diff | hist) Mass spectrometry 5,612 ±0 m add the sample preparation, since the result depends on it
  14. 04:24, 8 Feb 2026 (diff | hist) Beta cell function 6,096 ±0 the glucose-dependence of the insulinotropic effect deserves its own sentence
  15. 10:15, 7 Feb 2026 (diff | hist) Talk:Mass spectrometry 400 +196 /* Deamidation and unit resolution */ new section
  16. 18:51, 5 Feb 2026 (diff | hist) Peptide synthesis 5,649 ±0 clarify that "cold chain" without a logger is a claim, not a record
  17. 19:07, 18 Jan 2026 (diff | hist) Mass spectrometry 5,612 ±0 clarify the difference between related substances and total impurities
  18. 03:22, 30 Dec 2025 (diff | hist) Peptide content 8,404 ±0 state the mass accuracy in parts per million rather than daltons
  19. 06:32, 23 Oct 2025 (diff | hist) Vial 25,466 +442 m rm the shipping recommendation — that is advice, not description
  20. 10:18, 19 Sep 2025 (diff | hist) Electrospray ionisation 4,323 ±0 m add the equilibration time to the gradient description
  21. 09:00, 8 Sep 2025 (diff | hist) Syringe dead space 2,598 +2,598 N start article; worked example to follow
  22. 22:23, 26 Jul 2025 (diff | hist) Bachem Holding (Suzhou) 12,934 +810 ce
  23. 08:56, 22 Jun 2025 (diff | hist) Certificate of analysis 8,863 +270 add the turnaround time the service publishes
  24. 08:25, 15 Jun 2025 (diff | hist) Methionine oxidation 3,850 ±0 m expand §Detection and control
  25. 14:12, 22 May 2025 (diff | hist) Deamidation 4,219 ±0 rm the vendor name from a methodological sentence
  26. 14:25, 10 May 2025 (diff | hist) Area percent purity 6,569 ±0 state the column chemistry and the gradient the figure was obtained on
  27. 19:23, 5 May 2025 (diff | hist) Personal importation policy 3,251 ±0 m clarify the difference between a marketing authorisation and a registration
  28. 15:08, 26 Apr 2025 (diff | hist) STEP trial programme 4,391 +34 state the analysis population: intention-to-treat or per-protocol
  29. 08:54, 28 Mar 2025 (diff | hist) WuXi TIDES 10,186 ±0 split §Operations from §Product range
  30. 14:58, 14 Mar 2025 (diff | hist) Area percent purity 6,569 ±0 fix hyphenation per PP:MOS
  31. 14:29, 5 Mar 2025 (diff | hist) Talk:ChinaPeptides 748 +164 /* Custom synthesis needs its own risk paragraph */ reply
  32. 10:32, 5 Mar 2025 (diff | hist) Orforglipron 4,056 +719 m fix the anchor on an internal link
  33. 20:45, 1 Mar 2025 (diff | hist) FLOW trial 3,169 ±0 expand §Results
  34. 11:34, 21 Dec 2024 (diff | hist) Karl Fischer titration 6,021 +23 m expand §Interferences
  35. 16:50, 6 Nov 2024 (diff | hist) Drug master file 1,551 ±0 add the note that a certificate of analysis has no regulatory standing
  36. 01:32, 6 Nov 2024 (diff | hist) Loss on drying 2,569 ±0 m add the forced-degradation conditions the claim rests on
  37. 17:49, 4 Nov 2024 (diff | hist) Sterile water for injection 2,419 ±0 m add the disclaimer that this is not administration guidance
  38. 22:37, 14 Oct 2024 (diff | hist) Adverse effects of GLP-1 receptor agonists 3,137 ±0 add the monitoring recommendation as attributed to the labelling
  39. 10:26, 5 Oct 2024 (diff | hist) Amylin receptor agonist 1,601 ±0 add short description
  40. 00:48, 5 Oct 2024 (diff | hist) PeptideMeter 2,760 +33 give the fields a compendially-complete certificate would carry
  41. 17:54, 18 Sep 2024 (diff | hist) Liquid chromatography-mass spectrometry 1,347 +1,347 N new article: analytical method, expansion welcome
  42. 16:08, 13 Sep 2024 (diff | hist) Area percent purity 2,608 +767 rm the claim that the method is stability-indicating without a forced-degradation study
  43. 08:29, 2 Sep 2024 (diff | hist) Subcutaneous injection 2,092 ±0 m add short description
  44. 09:00, 24 Jul 2024 (diff | hist) Analytical method validation 1,373 +1,373 N new article: analytical method, expansion welcome
  45. 09:00, 18 Jun 2024 (diff | hist) High-performance liquid chromatography 2,129 +2,129 N new article: analytical method, expansion welcome